Minimal Residual Disease in Hairy-cell Leukemia after Treatment with 2-chlorodeoxyadenosine

Konwalinka, G; Schirmer, Michael; Hilbe, Wolfgang; Fend, Falko; Geisen, Francoise; Knoblechner, Anton; Petzer, Andreas; Thaler, Josef

doi:10.1006/bcmd.1995.0016

Cited by 19 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The remarkable activity of the purine analogs has led to the examination of posttreatment bone marrow biopsies to detect MRD in patients otherwise in CR. Immunohistochemistry using anti-CD20 antibodies in paraffin-embedded biopsies is a useful technique (72)(73)(74)(75)(76)(77)(78). Depending on the criteria used, 13-51% of patients in apparent CR have evidence of MRD (72)(73)(74)(75).…”

Section: Evaluation Of Minimal Residual Diseasementioning

confidence: 99%

Current treatment strategies for patients with hairy cell leukemia

Tallman

2002

Rev Clin Exp Hematol

View full text Add to dashboard Cite

Section: Evaluation Of Minimal Residual Diseasementioning

confidence: 99%

Current treatment strategies for patients with hairy cell leukemia

Tallman

2002

Rev Clin Exp Hematol

View full text Add to dashboard Cite

“…In the present study 20 of 75 patients relapsed and a probability of 3-yr PFS according to Kaplan-Meier's method amounted to 75%. It has been reported recently that HCL patients treated with 1 course of 2-CdA who fulfilled the criteria of a CR based on conventional clinical and hematological data have minimal residual disease in bone marrow detected by immunohistochemical and molecular studies (33)(34)(35). It became evident that a single 2-CdA course was unable to eradicate leukemic cells completely from bone marrow and the persistent clone may be responsible for relapse in HCL (36).…”

Section: Discussionmentioning

confidence: 99%

2‐Chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7‐year experience in Poland

Robak

Błasińska-Morawiec

Błasiński

et al. 1999

European J of Haematology

View full text Add to dashboard Cite

Between January 1991 and December 1997, 103 patients, 97 with typical hairy cell leukemia (HCL) and 6 with HCL‐variant (HCL‐V) were treated with 2‐chlorodeoxyadenosine (2‐CdA) given as 2‐h infusion for 5 consecutive d at a daily dose 0.12 mg/kg. To our knowledge this is the largest cohort of HCL patients treated with this type of regimen. Median follow‐up amounted to 36 months. Fifty‐six of 97 patients with typical HCL were newly diagnosed and 41 were relapsed after previous treatment. Splenectomy as a first‐line therapy was performed in 23 patients and 18 remaining patients received prednisone, chlorambucil or interferon‐α (IFN‐α) alone or in combinations. Seventy‐five (77.3%) patients entered CR and 18 (18.6%) achieved PR, giving an overall response rate of 95.9%. The mean time of first CR duration amounting to 32 months (range 3–72) did not correlate to the number of 2‐CdA cycles. 2‐CdA was equally effective in treatment of newly diagnosed patients and patients who relapsed after previous therapeutic procedures. Relapse of the disease occurred in 20 of 75 patients who achieved CR after 2‐CdA and was usually manifested by very discrete changes in peripheral blood counts (neutropenia and/or relative lymphocytosis). The mean progression‐free survival (PFS) time in this group was 37.4 (range 10–66) months. Ten of 20 relapsed patients were retreated with 2‐CdA given an identical course to the first one. Seven patients entered second CR lasting 19+ (range 8–47) months and 3 experienced PR. This confirms the previous observations that 2‐CdA gives no resistance to leukemic clone. Ten remaining patients have not required retreatment so far and remain in a good clinical and hematological state. The results of HCL‐V treatment with 2‐CdA were poor. Only 2 patients achieved PR and 4 patients did not respond to this drug. Seven patients (5 with typical HCL and 2 with HCL‐V) died, 3 of causes unrelated to the disease. Second neoplasms were noted in 5 patients. 2‐CdA‐related side effects resulted mainly from myelosuppression and infectious complications. In conclusion we confirm the effectiveness of 2‐CdA in inducing CR in patients with typical HCL, but this drug is unable to completely eradicate the leukemic clone which results in the relapse of the disease. The real incidence of the relapse rate may be underestimated unless bone marrow biopsy is performed. The results of our study indicate that a 2‐h infusion of 2‐CdA in HCL patients is at least as effective as a 24‐h infusion but more convenient to the patients, and may be given on an outpatient basis.

show abstract

“…The patient did not respond to therapy with interferon-α. Bone marrow biopsies were examined immunohistochemically using the monoclonal antibody B-ly7 as reported earlier [11]. Using a JH probe, a B-cell clone was detected in the pretreat…”

Section: Patient and Methodsmentioning

confidence: 99%

“…2.4% B-ly 7-positive hairy cells were detected by immunostaining of a bone marrow specimen [11]. Examination of the bone marrow specimen by Southern blot analysis revealed positive immunoglobulin gene rearrangement, with deletion of the pretreatment band and appearance of a new rearranged band of different size in the Southern blot (fig.…”

Section: Patient and Methodsmentioning

confidence: 99%

New Rearrangement Pattern after Treatment of Hairy-Cell Leukemia with 2-Chlorodeoxyadenosine

et al. 2000

Self Cite

View full text Add to dashboard Cite

Leukemic hairy cells are clonally proliferating B-lymphoid cells with clonal rearrangements of genes for immunoglobulin chains. We describe a patient with a new hairy-cell clone after treatment with 2-chlorodeoxyadenosine (2-CdA). In this patient, a single course of 2-CdA resulted in good partial remission of hairy-cell leukemia, but Southern blot analysis of bone marrow biopsies and polymerase chain reaction using seminested amplifications with consensus primers revealed a new rearranged band 4 months after therapy with 2-CdA. Four years after therapy, the patient is in complete clinical remission and both bands disappeared during follow-up. The new rearranged band might have been related to prior treatment of hairy-cell leukemia with 2-CdA.

show abstract

Minimal Residual Disease in Hairy-cell Leukemia after Treatment with 2-chlorodeoxyadenosine

Cited by 19 publications

References 0 publications

Current treatment strategies for patients with hairy cell leukemia

Current treatment strategies for patients with hairy cell leukemia

2‐Chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7‐year experience in Poland

New Rearrangement Pattern after Treatment of Hairy-Cell Leukemia with 2-Chlorodeoxyadenosine

Contact Info

Product

Resources

About